As part of your daily routine as an active trader or investor, it's important to track the stocks in the market that are making the biggest percentage gains and the biggest percentage losses.

Stocks that are making large moves to the upside are favorites among short-term traders who want to capture some of that massive volatility. Stocks that are making big-percentage moves are usually in play because their sector is becoming attractive or they have a major fundamental catalyst such as a recent earnings release. Sometimes stocks making big moves have been hit with an analyst upgrade or an analyst downgrade.

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits. If you time your trade correctly, combining with fundamental trends, discipline and sound money management, you will be well on your way to investment success.

With that in mind, let's take a closer look at a several stocks under $10 that are making large moves to the upside.

Avalanche Biotechnologies

  • Tuesday's Range: $7.40-$8.05
  • 52-Week Range: $7.40-$62.48
  • Tuesday's Volume: 512,000
  • Three-Month Average Volume: 558,257

Avalanche Biotechnologies  (AAVL) , a clinical-stage biotechnology company, focuses on discovering and developing novel gene therapies for the treatment of ophthalmic diseases based on its Ocular BioFactory platform. This stock traded up 7.2% to $8.03 in Tuesday's trading session.

From a technical perspective, Avalanche Biotechnologies ripped sharply higher on Tuesday right around some previous support levels at $7.77 to $7.80 a share with decent upside volume flows. This sharp spike to the upside is now quickly pushing this stock within range of triggering a major breakout trade above some key near-term overhead resistance levels. That trade will trigger if this stock manages to take out some near-term overhead resistance levels at its 20-day moving average of $8.19 to some more key resistance levels at $8.71 to $8.90 a share with high volume.

Traders should now look for long-biased trades in Avalanche Biotechnologies as long as it's trending above Tuesday's intraday low of $7.40 a share and then once it sustains a move or close above those breakout levels with volume that hits near or above 558,257 shares. If that breakout hits soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at its 50-day moving average of $9.49 to $10, or even $11.50 a share.

Amicus Therapeutics

  • Tuesday's Range: $6.45-$6.89
  • 52-Week Range: $5.37-$18.83
  • Tuesday's Volume: 2.74 million
  • Three-Month Average Volume: 3.73 million

Amicus Therapeutics  (FOLD - Get Report) , a biopharmaceutical company, develops and commercializes therapeutic products for rare and orphan diseases. This stock traded up 4.5% to $6.87 in Tuesday's trading session.

From a technical perspective, Amicus Therapeutics spiked sharply higher on Tuesday right above some near-term support at $6 a share with decent upside volume flows. This stock recently formed a double bottom chart pattern, after shares found some buying interest at $5.69 to $5.86 a share. Following that bottom, this stock has now started to spike higher and it's quickly moving within range of triggering a big breakout trade. That breakout will trigger if shares of Amicus Therapeutics manages to take out some near-term overhead resistance levels at $7 to $7.44 a share and then above its 20-day at $7.49 and over more resistance levels at $7.71 to around $8 a share with high volume.

Traders should now look for long-biased trades in Amicus Therapeutics as long as it's trending above some near-term support levels at $6 or at $5.86 and then once it sustains a move or close above those breakout levels with volume that hits near or above 3.73 million shares. If that breakout triggers soon, then this stock will set up to re-test or possibly take out its next major overhead resistance level at $10 a share.

Tetraphase Pharmaceuticals

  • Tuesday's Range: $8.51-$8.84
  • 52-Week Range: $7.20-$52.90
  • Tuesday's Volume: 923,000
  • Three-Month Average Volume: 1.92 million

Tetraphase Pharmaceuticals  (TTPH - Get Report) , a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multi-drug resistant infections. This stock traded up 2.4% to $8.82 in Tuesday's trading session.

From a technical perspective, Tetraphase Pharmaceuticals spiked notably higher here right off its 20-day moving average of $8.67 a share with lighter-than-average volume. This stock has been consolidating and trending sideways over the last month or so, with shares moving between $8.05 on the downside and $9.62 on the upside. This spike to the upside on Tuesday is now starting to push shares of Tetraphase Pharmaceuticals within range of triggering a major breakout trade above some near-term overhead resistance levels. That breakout will trigger if this stock manages to take out some near-term overhead resistance levels at $9.02 to $9.55 and then above more key resistance at $9.62 with high volume.

Traders should now look for long-biased trades in Tetraphase Pharmaceuticals as long as it's trending above some near-term support levels at around $8.26 to $8.05 a share and then once it sustains a move or close above those breakout levels with volume that hits near or above 1.92 million shares. If that breakout kicks off soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $11 to $12.84 a share. Any high-volume move over $12.84 will then give this stock a chance to re-fill some of its previous gap-down-day zone from September that started near $45 a share.


Vital Therapies

  • Tuesday's Range: $6.85-$7.87
  • 52-Week Range: $2.81-$29.67
  • Tuesday's Volume: 738,000
  • Three-Month Average Volume: 826,134

Vital Therapies  (VTL)  focuses on developing a cell-based therapy for the treatment of acute liver failure in the U.S. This stock traded up 4.2% to $7.55 in Tuesday's trading session.

From a technical perspective, Vital Therapies spiked notably higher on Tuesday with decent upside volume flows. This stock has been uptrending strong over the last two months, with shares moving higher off its low of $2.83 to its recent high of $7.89 a share. During that uptrend, this stock has been making mostly higher lows and higher highs, which is bullish technical price action. This strong move to the upside on Tuesday is now quickly pushing shares of Vital Therapies within range of triggering a major breakout trade. That trade will trigger if this stock manages to take out some key near-term overhead resistance at $7.89 with high volume.

Traders should now look for long-biased trades in Vital Therapies as long as it's trending above some near-term support levels at around $6.50 to $6 a share and then once it sustains a move or close above $7.89 a share with volume that registers near or above 826,134 shares. If that breakout hits soon, then this stock will set up to re-fill some of its previous gap-down-day zone from August that stared near $18 a share.

Ocular Therapeutix

  • Tuesday's Range: $7.15-$7.74
  • 52-Week Range: $6.75-$44.19
  • Tuesday's Volume: 839,000
  • Three-Month Average Volume: 261,346

Ocular Therapeutix  (OCUL - Get Report) , a biopharmaceutical company, focuses on the development and commercialization of therapies for eye diseases and conditions using its proprietary hydrogel platform technology in the U.S. This stock traded up 3.1% to $7.53 in Tuesday's trading session.

From a technical perspective, Ocular Therapeutix spiked notably higher here right above its new 52-week-low of $5.74 a share with strong upside volume flows. This stock recently gapped down sharply from around $16 a share to its new 52-week-low of $6.74 a share with heavy downside volume flows. Since that move, shares of Ocular Therapeutix have started to rebound off that $6.74 low and it's now quickly moving within range of triggering a near-term breakout trade. That breakout will trigger if this stock manages to take out some near-term overhead resistance at $8 a share with high volume.

Traders should now look for long-biased trades in Ocular Therapeutix as long as it's trending above Tuesday's intraday low of $7.15 or above its recent 52-week-low of $6.74 and then once it sustains a move or close above $8 a share with volume that hits near or above 261,346 shares. If that breakout develops soon, then this stock will set up to re-fill some of its previous gap-down-day zone that started near $16 a share. Some possible upside targets in the short-term are $10 to $12 a share.

Disclosure: This article is commentary by an independent contributor. At the time of publication, the author held no positions in the stocks mentioned.